-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ruxoprubart in Paroxysmal Nocturnal Hemoglobinuria
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ruxoprubart in Paroxysmal Nocturnal Hemoglobinuria report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ruxoprubart in Paroxysmal Nocturnal Hemoglobinuria Drug Details: Ruxoprubart (NM-8074) is...
-
Product Insights
Fora C3 Lytyachi Solar PV Park
Fora C3 Lytyachi Solar PV Park is a solar PV project located in Ternopil, Ukraine. The project came online in 2019. Empower your strategies with our Fora C3 Lytyachi Solar PV Park report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business day of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Iptacopan Hydrochloride in Membranoproliferative Glomerulonephritis (Mesangiocapillary Glomerulonephritis)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Iptacopan Hydrochloride in Membranoproliferative Glomerulonephritis (Mesangiocapillary Glomerulonephritis) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Iptacopan Hydrochloride in Membranoproliferative Glomerulonephritis (Mesangiocapillary Glomerulonephritis) Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Iptacopan Hydrochloride in Proteinuria
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Iptacopan Hydrochloride in Proteinuria report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Iptacopan Hydrochloride in Proteinuria Drug Details: Iptacopan hydrochloride (Fabhalta) is a factor B...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Danicopan in Paroxysmal Nocturnal Hemoglobinuria
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Danicopan in Paroxysmal Nocturnal Hemoglobinuria report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Danicopan in Paroxysmal Nocturnal Hemoglobinuria Drug Details: Danicopan (Voydeya) is a...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Iptacopan Hydrochloride in Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Iptacopan Hydrochloride in Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Iptacopan Hydrochloride in Idiopathic Thrombocytopenic Purpura...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Iptacopan Hydrochloride in Acquired (Autoimmune) Hemolytic Anemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Iptacopan Hydrochloride in Acquired (Autoimmune) Hemolytic Anemia report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Iptacopan Hydrochloride in Acquired (Autoimmune) Hemolytic Anemia Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Iptacopan Hydrochloride in Glomerulonephritis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Iptacopan Hydrochloride in Glomerulonephritis report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Iptacopan Hydrochloride in Glomerulonephritis Drug Details: Iptacopan hydrochloride (Fabhalta) is a factor...
-
Company Insights
Innovation and Patenting activity of C3.ai Inc Q1 2024
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of C3.ai Inc Q1 2024". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be delivered...